22.01.2018 • NewsAdamaChemChinaElaine Burridge

Adama Raises Funds for Growth

ChemChina subsidiary Adama has raised nearly 1.6 billion Chinese yuan to fund...
ChemChina subsidiary Adama has raised nearly 1.6 billion Chinese yuan to fund certain designated investments (c) Fuse/Getty Images

ChemChina subsidiary Adama has raised nearly 1.6 billion Chinese yuan ($243.8 million) to fund certain designated investments.

These include ramping up capacity at its recently commissioned formulation plant in Huai’An, China, and installing and expanding manufacturing facilities in Israel, Brazil and the US. Adama said it will also use the money to further develop its global product portfolio.

The funds were raised from six Chinese institutional investors. Adama sold 104.7 million new shares at 14.90 yuan each, taking the company’s aggregate market capitalization to $6.14 billion. The new shares were listed on the Shenzhen Stock Exchange as of Jan. 17.

 “This capital raise demonstrates our ability to benefit from the significant equity capital market in China, one of the key aims of our combination and flotation. Following our recent inclusion in the Shenzhen-Hong Kong Stock Connect, Adama now represents a unique opportunity for both Chinese and global investors. The proceeds we raised will be put to good use in supporting our key global growth initiatives in the coming years,” said chief financial officer, Aviram Lahav.

Adama Agricultural Solutions merged with Hubei Sanonda, which is also a ChemChina subsidiary, last September.

Earlier this month, Adama inaugurated a new R&D center in Nanjing, which it said is China’s life science and biotech focal point. The center will develop new products and formulations, improve existing manufacturing processes and support several functions in the country such as registration, marketing, sales as well as various supply chain activities.

Whitepaper

Excellence in Pharmaceutical Distribution and The Critical Role of Good Distribution Practice (GDP)
Setting the Standard

Excellence in Pharmaceutical Distribution and The Critical Role of Good Distribution Practice (GDP)

Are you ready to elevate your pharmaceutical operations? Download our exclusive whitepaper and discover how compliance with Good Distribution Practice (GDP) is essential for the safety and integrity of pharmaceuticals.

Virtual Event

Digitalization in the Chemical Industry
CHEManager Spotlight

Digitalization in the Chemical Industry

Save the Date: October 22, 2025
The event will be promoted to a combined audience of over 100,000 professionals across Europe through the CHEManager and CITplus networks.

most read

Photo
22.04.2025 • News

BASF Divests Two Joint Ventures in China

BASF has divested its shares in the joint venture companies, BASF Markor Chemical Manufacturing (Xinjiang) Co., Ltd. and Markor Meiou Chemical (Xinjiang) Co., Ltd. in Korla, China, to Verde Chemical Singapore Pte. Ltd.

Photo
13.03.2025 • News

Roche and Zealand Pharma Collaborate on Weight Management Drug

Swiss pharma heavyweight Roche announced has entered into an exclusive collaboration and licensing agreement with Denmark’s Zealand Pharma. Under the terms of this agreement, the two companies will collaborate to co-develop and co-commercialize petrelintide, Zealand Pharma’s amylin analog as a standalone therapy as well as a fixed-dose combination with Roche’s lead incretin asset CT-388.